To clarify the relationship between coagulation mediators and the target therapy in melanoma, and in particular the modulation of the coagulation cascade in BRAFv600 mutated melanoma patients upon BRAF inhibitors, we herein investigated the effects of BRAF and MEK inhibitors, alone or in association, on TF expression in BRAFv600e mutated melanoma cell lines. The gene discussed is MAP2K7; the disease is melanoma.